Suchen und Finden
Manual of Pediatric Hematology and Oncology
von: Philip Lanzkowsky (Ed.)
Elsevier Trade Monographs, 2010
ISBN: 9780123751553 , 1058 Seiten
5. Auflage
Format: PDF, ePUB, OL
Kopierschutz: DRM
Preis: 118,00 EUR
Front Cover
1
Manual of Pediatric Hematology and Oncology
4
Copyright Page
5
Contents
6
Dedication
8
Contributors
10
Introduction
16
Preface to the Fifth Edition
23
Preface to the Fourth Edition
25
Preface to the Third Edition
27
Preface to the Second Edition
29
Preface to the First Edition
30
Chapter 1. Classification and Diagnosis of Anemia in Children
32
Suggested Reading
44
Chapter 2. Anemia During the Neonatal Period
45
Hemorrhage
45
Hemolytic Anemia
50
Failure of Red Cell Production
64
Anemia of Prematurity
64
Physiologic Anemia
66
Diagnostic Approach to Anemia in the Newborn
66
Suggested Reading
68
Chapter 3. Iron-Deficiency Anemia
69
Prevalence
69
Etiologic Factors
69
Non-Hematological Manifestations
75
Diagnosis
75
Treatment
84
Suggested Reading
88
Chapter 4. Megaloblastic Anemia
89
Vitamin B[sub(12)] (Cobalamin) Deficiency
89
Folic Acid Deficiency
104
General Clinical Features of Cobalamin and Folate Deficiency
111
Diagnosis
112
Treatment
115
Suggested Reading
117
Chapter 5. Hematologic Manifestations of Systemic Illness
118
Hematologic Manifestations of Diseases of Various Organs
118
Chronic Illness
127
Lead Intoxication
140
Nutritional Disorders
140
Bone Marrow Infiltration
141
Suggested Reading
153
Chapter 6. Bone Marrow Failure
154
Aplastic Anemia
154
Acquired Aplastic Anemia
157
Congenital Aplastic Anemias
169
Dyskeratosis congenita
178
Congenital Aplastic Anemias of Unknown Inheritance
181
Diamond-Blackfan Anemia (Congenital Pure Red Cell Aplasia)
182
Transient Erythroblastopenia
188
Congenital Dyserythropoietic Anemia (CDA)
189
Sideroblastic Anemias (Mitochondrial Diseases with Bone Marrow Failure Syndromes)
193
Suggested Reading
197
Chapter 7. Red Cell Membrane and Enzyme Defects
199
General Approach to Diagnosis of Hemolytic Anemia
199
Membrane Defects
203
Paroxysmal Nocturnal Hemogloginuria
216
Enzyme Defects
222
Suggested Reading
230
Chapter 8. Hemoglobinopathies
231
Sickle Cell Disease
231
Unstable Hemoglobins
261
Thalassemias
262
β-Thalassemia: Homozygous or Doubly Heterozygous Forms (Major and Intermedia)
265
β-Thalassemia Intermedia
275
β-Thalassemia Minor or Trait (Heterozygous β[sup(0)] or β+)
276
α-Thalassemias
276
Suggested Reading
276
Chapter 9. Extracorpuscular Hemolytic Anemia
278
Immune Hemolytic Anemia
278
Nonimmune Hemolytic Anemia
285
Suggested Reading
287
Chapter 10. Polycythemia
288
Polycythemia (Erythrocytosis) in the Newborn
288
Polycythemia in Childhood
292
Polycythemia Vera
293
Primary Familial and Congenital Polycythemia
296
Congenital Polycythemia Due to Altered Hypoxia Sensing with Normal P50
297
Prolyl Hydroxylase Domain (PHD) 2 Mutations
299
Congenital Polycythemia Due to Altered Hypoxia Sensing with Decreased P50
299
Other Causes of Polycythemia
300
Diagnostic Approach
300
Suggested Reading
302
Chapter 11. Disorders of White Blood Cells
303
Quantitative Disorders of Leukocytes
303
Decreased Polymorphonuclear Leukocyte Production
309
Increased Destruction or Disorders of Distribution of Polymorphonuclear Leukocytes
320
Eosinophils
326
Lymphocytes
333
Neutrophil Production and Destruction in Newborn Infants
349
Suggested Reading
350
Chapter 12. Disorders of Platelets
352
Thrombocytopenia in the Newborn
352
Inherited Thrombocytopenias
366
Thrombocytopenia in Childhood
374
Thrombocytosis
390
Qualitative Platelet Disorders
393
Acquired Platelet Disorders
400
Inherited Vascular and Connective Tissue Disorders
403
Laboratory Evaluation of Platelets and Platelet Function
404
Nonthrombocytopenic Purpura
406
Suggested Reading
407
Chapter 13. Hemostatic Disorders
409
Physiology of Hemostasis
409
Fibrinolysis
413
Natural Inhibitors of Coagulation
414
Hemostasis in the Newborn
416
Detection of Hemostatic Defects
418
Acquired Coagulation Factor Disorders
421
Inherited Coagulation Factor Disorders
426
Rare Inherited Coagulation Factor Disorders (Factor II, V, VII, X, XIII, Fibrinogen Deficiencies)
447
Hereditary Disorders of Platelet Function
448
Suggested Reading
449
Chapter 14. Thrombotic Disorders
450
Mechanisms of Thrombosis in Inherited Thrombophilia
450
Venous Thrombosis
450
Arterial Thrombosis
452
Antiphospholipid Syndrome
461
Hereditary Thrombotic Disorders
467
Thrombotic Disorders in Newborns
474
Antithrombotic Agents
476
Heparin-induced Thrombocytopenia
481
Thrombolytic Therapy
486
Antithrombotic Therapy in Special Conditions
489
Suggested Reading
491
Chapter 15. Lymphadenopathy and Splenomegaly
492
Lymphadenopathy
492
Splenomegaly
499
Suggested Reading
502
Chapter 16. Lymphoproliferative Disorders, Myelodysplastic Syndromes and Myeloproliferative Disorders
503
Lymphoproliferative Disorders
503
Myelodysplastic Syndrome
525
Juvenile Myelomonocytic Leukemia (JMML)
534
Chronic Myeloproliferative Diseases
539
Chronic Myeloid Leukemia (CML)
539
Suggested Reading
547
Chapter 17. Leukemias
549
Incidence
549
Etiology
549
Clinical Features of Acute Lymphoblastic Leukemia (ALL)
550
Acute Myeloid Leukemia
581
Suggested Reading
595
Chapter 18. Histiocytosis Syndromes
598
Langerhans Cell Histiocytosis
598
Other Histiocytic Disorders
616
Dermal Dendrocyte Disorders
616
Suggested Reading
627
Chapter 19. Hodgkin Lymphoma
630
Etiology and Epidemiology
630
Risk Factors
630
Biology
631
Pathology
631
Clinical Presentation
634
Diagnostic Evaluation and Staging
638
Prognostic Factors
640
Treatment
642
Long-term Complications
648
Follow-up Evaluations
652
Suggested Reading
653
Chapter 20. Non-Hodgkin Lymphoma
655
Introduction
655
Incidence and Epidemiology
655
Pathologic Classification
656
Clinical Features
656
Diagnosis
661
Staging
661
Management
662
Lymphoblastic Lymphoma
663
B lineage NHL (BC, BLL and DLCL)
664
Suggested Reading
676
Chapter 21. Central Nervous System Malignancies
678
Pathology
678
Clinical Manifestations
680
Diagnostic Evaluation
682
Treatment
685
Astrocytomas
688
Medulloblastoma
691
Brain Stem Tumors
694
Ependymomas
695
Optic Glioma
696
Craniopharyngiomas
698
Intracranial Germ Cell Tumors
699
Malignant Brain Tumors in Infants and Children Less than 3 Years of Age
700
Suggested Reading
701
Chapter 22. Neuroblastoma
702
Epidemiology
702
Predisposition
702
Pathology and Biology
702
Clinical Features
703
Neuroblastoma in the Neonate
706
Diagnosis and Staging
706
Prognosis and Risk Stratification
708
Treatment
710
Disease Stratification and Therapy
712
Post-Therapy Monitoring
721
Special Treatment Considerations
723
Neuroblastoma in the Adolescent and Young Adult
724
Suggested Reading
724
Chapter 23. Renal Tumors
726
Wilms' Tumor
726
Nephroblastomatosis
742
Congenital Mesoblastic Nephroma
742
Clear Cell Sarcoma of the Kidney
743
Rhabdoid Tumor of the Kidney
744
Renal Cell Carcinoma (RCC)
744
Suggested Reading
744
Chapter 24. Rhabdomyosarcoma and Other Soft-Tissue Sarcomas
746
Incidence and Epidemiology
746
Pathologic Classification
749
Genetics
749
Clinical Features
750
Diagnostic Evaluation
752
Staging
753
Prognosis
756
Treatment
758
Follow-Up After Completion of Therapy
765
Recurrent Disease
766
Future Perspectives
767
Suggested Reading
768
Chapter 25. Malignant Bone Tumors
770
Osteosarcoma
770
Ewing Sarcoma
780
Suggested Reading
788
Chapter 26. Retinoblastoma
790
Incidence
790
Classification
790
Other Epidemiologic Data
793
Risk for Second Malignant Neoplasms (SMN)
794
Pathology
794
Clinical Features
795
Diagnostic Procedures
796
Staging
797
Treatment
799
Post-Treatment Management
804
Future Perspectives
805
Suggested Reading
806
Chapter 27. Germ Cell Tumors
807
Incidence
807
Pathology
807
Clinical Features
808
Diagnostic Evaluation
812
Tumor Markers
813
Staging
814
Treatment
815
Relapsed and Resistant Germ Cell Tumors
824
Suggested Reading
825
Chapter 28. Hepatic Tumors
827
Incidence
827
Epidemiology
827
Pathology
828
Clinical Features
829
Diagnostic Evaluation
829
Staging
832
Treatment
832
Prognosis
835
Suggested Reading
836
Chapter 29. Hematopoietic Stem Cell Transplantation
837
Solid Tumors
840
Allogeneic Stem Cell Transplantation
841
Engraftment
850
Graft Versus Host Disease (GVHD)
851
Autologous Stem Cell Transplantation
852
Complications of Hematopoietic Stem Cell Transplantation
854
Late Sequelae of Stem Cell Transplantation
866
Post-Stem Cell Transplantation Therapy
866
Suggested Reading
868
Chapter 30. Management of Oncologic Emergencies
870
Metabolic and Endocrine Emergencies
870
Oncologic Emergencies by Anatomic Region
879
Suggested Reading
887
Chapter 31. Supportive Care of Patients with Cancer
888
Management of Infectious Complications
888
Bacterial Infections
897
Fungal Infections
899
Viral Infections
905
Protozoan Infections
906
G-CSF and Granulocyte Infusions
907
Immunizations
907
Blood Component Therapy
909
Hematopoietic Growth Factors: Basic Biology of Growth Factors
917
Clinical use of G-CSF, GM-CSF, Erythropoietin and IL-11
919
Prevention of Organ Toxicity
923
Pain Management
927
General Guidelines for Management of Pain in Oncology Patients
933
Management of Nausea and Vomiting
935
Nutritional Support
944
Psychosocial Support and End-of-Life Care
949
Suggested Reading
949
Chapter 32. Evaluation, Investigations and Management of Late Effects of Childhood Cancer
952
Musculoskeletal Dysfunction
953
Cardiovascular Disorders
959
Respiratory System
961
Central Nervous System
964
Endocrine System
967
Genitourinary System
973
Ocular System
975
Auditory System
976
Gastrointestinal System
977
Immunologic System
977
Obesity
978
Second Malignant Neoplasms
978
Suggested Reading
981
Chapter 33. Psychosocial Aspects of Cancer for Children and their Families
983
Diagnosis
983
Treatment Initiation
989
Illness Stabilization
990
Relapses and Recurrences
991
Treatment Outcomes: The Unsuccessful Course
992
Treatment Outcomes: The Successful Course
995
Survivorship
995
Conclusion
997
Suggested Reading
997
Appendix 1 Hematological Reference Values
1000
Red Cell Values and Related Serum Values
1000
White Cell Values
1012
Platelet Values
1013
Coagulation Values
1014
Bone Marrow Cells
1022
Appendix 2 Biological Tumor Markers
1026
Appendix 3 Pharmacologic Properties of Commonly used Anticancer Drugs
1028
Index
1036
A
1036
B
1038
C
1039
D
1041
E
1042
F
1043
G
1043
H
1044
I
1047
J
1048
K
1048
L
1048
M
1049
N
1050
O
1051
P
1052
Q
1053
R
1053
S
1054
T
1055
U
1057
V
1057
W
1057
X
1058
Y
1058
Alle Preise verstehen sich inklusive der gesetzlichen MwSt.